Sayantan Ray

ORCID: 0000-0002-6274-465X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuropeptides and Animal Physiology
  • Streptococcal Infections and Treatments
  • Diabetic Foot Ulcer Assessment and Management
  • Digestive system and related health
  • Pharmacology and Obesity Treatment
  • Sexual Differentiation and Disorders
  • Vitamin D Research Studies
  • Diabetes Treatment and Management
  • Wound Healing and Treatments
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Hormonal and reproductive studies
  • Growth Hormone and Insulin-like Growth Factors

All India Institute of Medical Sciences Bhubaneswar
2022-2024

46, XY difference/disorder of sex development (DSD) is a relatively uncommon group heterogeneous disorders with varying degree underandrogenization male genitalia. Such patients should be approached systematically to reach an aetiological diagnosis. However, we lack, at present, clinical practice guideline on diagnostic approach in DSD from this part the globe. Moreover, debate persists regarding timing and cut-offs different hormonal tests, performed these cases. The consensus committee...

10.1515/jpem-2022-0515 article EN Journal of Pediatric Endocrinology and Metabolism 2022-11-25

Rickets, one of the leading causes bony deformities and short stature, can be calciopenic (inciting event is defective intestinal calcium absorption) or phosphopenic phosphaturia). Early diagnosis timely treatment rickets are crucial for correction limb deformities. Guidelines exist nutritional rickets, but management relatively uncommon forms complex. This consensus aims to formulate a simplified diagnostic approach especially in resource-limited settings. The statement has been formulated...

10.6065/apem.2448044.022 article EN cc-by-nc Annals of Pediatric Endocrinology & Metabolism 2024-10-30

The twin epidemics of Type 2 diabetes (T2D) and obesity will continue to bring significant health challenges in the coming decades. Randomised controlled trials glucagon-like peptide 1 (GLP-1)-based therapies showed high glycaemic efficacy with clinically meaningful weight loss, have been considered as game-changers diabesity population. Emerging evidence has demonstrated that co-administration glucose-dependent insulinotropic (GIP) GLP-1 results enhanced effect an additive way...

10.33590/emjdiabet/22-00140 article EN cc-by-nc EMJ Diabetes 2022-07-25
Coming Soon ...